At 3.9% CAGR, Europe Epilepsy Market is Projected to be Worth US$ 2,626.05 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030, registering a CAGR of 3.9% from 2022 to 2030. Surge in awareness programs conducted by organizations and increasing investments in development of epilepsy therapies are among the critical factors attributed to drive the Europe epilepsy market growth.

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. The UK Sudden Unexpected Death in Epilepsy (SUDEP) Awareness Day is celebrated on October 23. The SUDEP action leads the international epilepsy community to recognize and raise awareness about sudden and unexpected death due to epilepsy. Furthermore, the International League Against Epilepsy and the International Bureau for Epilepsy have sanctioned Epilepsy Alliance Europe, a non-profit organization. It includes various programs, such as e-pilepsy, EpiCARE, and ESBACE. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

On the contrary, recall of products hampers the growth of Europe epilepsy market.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held 50.9% market share in 2022, amassing US$ 986.95 million. It is projected to garner US$ 1,394.80 million by 2030 to register 4.4% CAGR during 2022-2030.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held 69.3% share of Europe epilepsy market in 2022, amassing US$ 1,345.20 million. It is anticipated to garner US$ 1,905.06 million by 2030 to expand at 4.4% CAGR during 2022-2030.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held 42.7% share of Europe epilepsy market in 2022, amassing US$ 829.26 million. It is projected to garner US$ 1,161.48 million by 2030 to expand at 4.3% CAGR from 2022 to 2030.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held 81.5% share of Europe epilepsy market in 2022, amassing US$ 1,580.85 million. It is predicted to garner US$ 2,218.03 million by 2030 to expand at 4.3% CAGR between 2022 and 2030.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 51.2% share of Europe epilepsy market in 2022, amassing US$ 993.59 million. It is projected to garner US$ 1,301.55 million by 2030 to expand at 3.4% CAGR from 2022 to 2030.

By country, the Europe epilepsy market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that the UK captured 23.8% share of Europe epilepsy market in 2022. It was assessed at US$ 461.93 million in 2022 and is likely to hit US$ 664.36 million by 2030, registering a CAGR of 4.6% during 2022-2030.

Key players operating in the Europe epilepsy market are Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS, among others.

• In January 2024, CombiGene AB announced that it has regained the global rights to the epilepsy project CG01 from Spark Therapeutics as the termination period of the collaboration and license agreement between the two companies was expired in October 2023.
  
  
  
• In May 2023, the biotechnology company Neuro3 Therapeutics (Neuro3), which focuses on finding and creating novel medications to treat illnesses of the central nervous system has signed an exclusive global license and option deal with Lundbeck. The agreement focuses on KCNQ2 ion channel activators, which have been clinically verified as targets for epilepsy treatment. According to clinical research, KCNQ2 channel activation may offer therapeutic alternatives for treating various neurological conditions, such as uncommon forms of epilepsy. The agreement states that Neuro3 will be in charge of developing the two clinical stage and one pre-clinical stage KCNQ2 activator program further through clinical proof-of-concept (PoC). Neuro3 will also obtain a worldwide license for intellectual property related to these products. Lundbeck and Neuro3 may choose to co-develop and co-commercialize after the PoC experiments are finished. Furthermore, Lundbeck has the ability to re-exclusively lease the rights back in specific regions.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com